Reata Pharmaceuticals, Inc. - (RETA) News

Reata Pharmaceuticals, Inc. - (RETA): $20.77

-1.27 (-5.76%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter RETA News Items

RETA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RETA News Highlights

  • RETA's 30 day story count now stands at 9.
  • Over the past 26 days, the trend for RETA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about RETA are DRUG, ACT and CRL.

Latest RETA News From Around the Web

Below are the latest news stories about Reata Pharmaceuticals Inc that investors may wish to consider to help them evaluate RETA as an investment opportunity.

Reata slips as FDA rejects kidney disease therapy

Reata Pharmaceuticals (NASDAQ:RETA) has lost ~4% in the post-market Friday after the company announced that the U.S. Food and Drug Administration (“FDA”) issued a Complete Response Letter (CRL) regarding its New Drug Application (“NDA”) for bardoxolone methyl (“bardoxolone”). With its NDA, the clinical-stage biopharmaceutical company had sought the U.S. regulatory clearance for...

Seeking Alpha | February 26, 2022

Reata Pharmaceuticals Receives Complete Response Letter From The FDA for Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome

PLANO, Texas, February 25, 2022--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," or "we"), today announced that the U.S. Food and Drug Administration ("FDA") has issued a Complete Response Letter ("CRL") regarding the New Drug Application ("NDA") for bardoxolone methyl ("bardoxolone") for the treatment of patients with chronic kidney disease ("CKD") caused by Alport syndrome.

Yahoo | February 25, 2022

Earnings Preview: Reata Pharmaceuticals, Inc. (RETA) Q4 Earnings Expected to Decline

Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 21, 2022

Reata Pharmaceuticals, Inc. To Report Fourth Quarter and Full Year 2021 Financial Results and To Provide an Update on Development Programs on February 28, 2022

PLANO, Texas, February 18, 2022--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," "our," "us," or "we"), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on the Company’s business operations and clinical development programs pre-market on February 28, 2022.

Yahoo | February 18, 2022

Biondo Investment Advisors, LLC Buys Unity Software Inc, Coinbase Global Inc, PNC Financial ...

Milford, PA, based Investment company Biondo Investment Advisors, LLC (Current Portfolio) buys Unity Software Inc, Coinbase Global Inc, PNC Financial Services Group Inc, sells Intuitive Surgical Inc, Reata Pharmaceuticals Inc, Teladoc Health Inc, Align Technology Inc, 10x Genomics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Biondo Investment Advisors, LLC.

Yahoo | February 8, 2022

Silvant Capital Management LLC Buys Netflix Inc, Pfizer Inc, Natera Inc, Sells Visa Inc, ...

Investment company Silvant Capital Management LLC (Current Portfolio) buys Netflix Inc, Pfizer Inc, Natera Inc, Union Pacific Corp, SentinelOne Inc, sells Visa Inc, Mastercard Inc, Comcast Corp, UnitedHealth Group Inc, Cardlytics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Silvant Capital Management LLC.

Yahoo | February 7, 2022

Act Capital Management, Llc Buys Adtran Inc, Meta Platforms Inc, Vir Biotechnology Inc, Sells , ...

Investment company Act Capital Management, Llc (Current Portfolio) buys Adtran Inc, Meta Platforms Inc, Vir Biotechnology Inc, AirSculpt Technologies Inc, enVVeno Medical Corp, sells , Upstart Holdings Inc, Affirm Holdings Inc, Nektar Therapeutics, Nuance Communications Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Act Capital Management, Llc.

Yahoo | February 3, 2022

Investors in Reata Pharmaceuticals (NASDAQ:RETA) from a year ago are still down 73%, even after 11% gain this past week

Reata Pharmaceuticals, Inc. ( NASDAQ:RETA ) shareholders should be happy to see the share price up 12% in the last...

Yahoo | February 2, 2022

Reata Pharmaceuticals Initiates Rolling Submission of New Drug Application with U.S. FDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia

PLANO, Texas, January 31, 2022--Reata Pharmaceuticals, Inc. (Nasdaq: RETA), ("Reata," the "Company," "our," "us," or "we"), a clinical-stage biopharmaceutical company, today announced that the company has initiated a rolling submission of a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for omaveloxolone for the treatment of patients with Friedreich’s ataxia. The rolling submission allows Reata to submit portions of the regulatory application to the FDA for review

Yahoo | January 31, 2022

Penn Davis Mcfarland Inc Buys Lockheed Martin Corp, Activision Blizzard Inc, Despegar. ...

Dallas, TX, based Investment company Penn Davis Mcfarland Inc (Current Portfolio) buys Lockheed Martin Corp, Activision Blizzard Inc, Despegar.com Corp, Independent Bank Group Inc, sells Inovalon Holdings Inc, Las Vegas Sands Corp, Matador Resources Co, Reata Pharmaceuticals Inc, Dorchester Minerals LP during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Penn Davis Mcfarland Inc.

Yahoo | January 20, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5747 seconds.